联合检测EB病毒不同抗体及EB病毒DNA在鼻咽癌血清学诊断中的价值

发布时间：2018-04-29 10:31

  本文选题：鼻咽癌 + 抗体　； 参考：《现代肿瘤医学》2016年19期

【摘要】：目的:评价EB病毒(EBV)抗衣壳抗原VCA-IgA抗体、抗早期抗原EA-IgA抗体、抗立即早期抗原Rta-IgG抗体和EBV-DNA检测在鼻咽癌诊断中的价值。方法:收集160例初治鼻咽癌,133例症状相似的非鼻咽癌患者和163名健康体检者的血清和血浆。采用酶联免疫法检测血清VCA-IgA、EA-IgA和RtaIgG抗体的水平,用实时荧光定量PCR检测血浆EBV-DNA的相对含量。按鼻咽癌2008临床TNM分期法进行分期,计算不同分组、各临床分期以及鼻咽癌治疗前后的各抗体阳性率、抗体水平以及EB-DNA的检测结果并进行数据分析。结果:鼻咽癌组VCA-IgA、EA-IgA、Rta-IgG和EBV-DNA阳性率均高于鼻咽相关疾病组及健康对照组(均P0.05)。血清VCA-IgA和EA-IgA结果相对A值(即r A或S/CO值)在Ⅰ、Ⅱ期低于Ⅲ、Ⅳ期,差异有统计学意义(P0.05),但阳性率在各期间比较差异无统计学意义(P0.05);Ⅰ、Ⅱ期患者Rta-IgG的r A值和阳性率明显低于Ⅲ、Ⅳ期患者(P0.05);血浆中EBV-DNA阳性率及EBVDNA中位数水平随着临床分期的升高而增高,Ⅰ、Ⅱ期与Ⅲ、Ⅳ期比较差异有统计学意义(P0.05)。治疗有效(CR+PR)患者的EBV-DNA含量明显低于治疗前水平(P0.05)。结论:VCA-IgA、EA-IgA、RtaIgG、EBV-DNA检测有助于鼻咽癌的辅助诊断、临床分期预测及疗效评估。
[Abstract]:Objective: to evaluate the value of Epstein-Barr virus (EBV) anti-capsid antigen VCA-IgA antibody, anti-early antigen EA-IgA antibody, anti-immediate early antigen Rta-IgG antibody and EBV-DNA detection in the diagnosis of nasopharyngeal carcinoma. Methods: the serum and plasma of 160 patients with nasopharyngeal carcinoma (NPC) with similar symptoms, 133 patients with non nasopharyngeal carcinoma (NNPC) and 163 healthy controls were collected. The levels of serum VCA-IgAEA-IgA and RtaIgG antibodies were detected by enzyme-linked immunosorbent assay (Elisa), and the relative content of plasma EBV-DNA was detected by real-time fluorescence quantitative PCR. According to the clinical TNM staging method of nasopharyngeal carcinoma (NPC) 2008, the positive rate of antibody, the level of antibody and the detection results of EB-DNA were calculated and analyzed in different groups, clinical stages and before and after treatment of nasopharyngeal carcinoma. Results: the positive rates of VCA-IgAEA-IgAEA-IgAEA-Rta-IgG and EBV-DNA in nasopharyngeal carcinoma group were higher than those in nasopharyngeal related disease group and healthy control group (all P 0.05). The relative A value of serum VCA-IgA and EA-IgA (i.e. r A or S/CO) in stage 鈪，

本文编号：1819561